問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

葉昭廷Yeh, Chau-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

  • chauting@cgmh.org.tw

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉昭廷

List

38Cases

2022-02-16 - 2026-12-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2023-02-01 - 2028-01-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2014-04-20 - 2016-05-20

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-11-01 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated11Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2021-11-01 - 2025-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2017-12-01 - 2020-08-05

Others

A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Chronic Hepatitis B Virus Infection

  • Test Drug

    JNJ-56136379

Participate Sites
4Sites

Terminated4Sites

葉昭廷
Linkou Chang Gung Medical Foundation

Digestive System Department

2017-01-01 - 2018-12-31

Phase I

A Phase 1, double-blind, randomized, placebo-controlled, first-in-human study of orally administered JNJ-56136379 to evaluate safety, tolerability and pharmacokinetics after single ascending doses and one multiple dose regimen in healthy subjects (Part I), and after multiple dose regimens in subjects with chronic hepatitis B (Part II)

  • Condition/Disease

    Chronic hepatitis B

  • Test Drug

    JNJ-56136379

Participate Sites
5Sites

Terminated5Sites

2008-12-01 - 2010-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-04-15 - 2018-08-27

Phase I

A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7049389 IN: (1) SINGLE- (WITH OR WITHOUT FOOD) AND MULTIPLE- (WITH MIDAZOLAM) ASCENDING DOSES IN HEALTHY VOLUNTEERS; (2) PATIENTS CHRONICALLY INFECTED WITH HEPATITIS B VIRUS

  • Condition/Disease

    HEPATITIS B VIRUS

  • Test Drug

    RO7049389

Participate Sites
7Sites

Recruiting6Sites

葉昭廷
Linkou Chang Gung Medical Foundation

2017-10-16 - 2019-05-31

Phase I

A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION

  • Condition/Disease

    CHRONIC HEPATITIS B VIRUS INFECTION

  • Test Drug

    RO7062931 sterile liquid for inection

Participate Sites
5Sites

Terminated4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB